Literature DB >> 8318511

Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.

S Venkatesan1, P Cullen, P Pacy, D Halliday, J Scott.   

Abstract

Familial combined hyperlipidemia (FCHL) may be genetically and metabolically more heterogeneous than previously thought. A consistent feature is an increase in circulating very-low-density lipoprotein (VLDL) apolipoprotein (apo) B, which could be due to either an increase in apoB production or a decrease in its catabolism. Therefore, we directly measured VLDL apoB production in the postabsorptive state in seven FCHL subjects (four male, three female) and seven normal control subjects (three male, four female) by using L-[1-13C]leucine as an endogenous label. Mean age and body mass index did not differ significantly between the two groups. The mean total cholesterol levels were 4.7 +/- 0.8 and 8.8 +/- 1.6 mmol/L (+/- SD, P < .01) and the mean triglyceride levels were 0.84 +/- 0.14 and 3.30 +/- 1.10 mmol/L (+/- SD, P < .01) in the control and FCHL groups, respectively. Although the fractional production rate of VLDL apoB was 38% lower in the FCHL group than in the control subjects (0.11 +/- 0.03 versus 0.18 +/- 0.02 pool/h; mean +/- SD, P < .01), its absolute production rate was 2.7 times greater (534 +/- 193 micrograms/kg per hour in FCHL versus 196 +/- 71 micrograms/kg per hour in control subjects; mean +/- SD, P < .01). There was a linear relation (r = 0.8, P = .03) between triglyceride levels and the VLDL apoB production rate in FCHL, the slope of which indicated a similar VLDL triglyceride-to-apoB ratio in the FCHL and control groups. We conclude that FCHL is a metabolically coherent disorder and that the increase in circulating apoB and triglyceride levels in FCHL is due to secretion of an increased number of VLDL particles, each containing, on average, a normal amount of triglyceride and one molecule of apoB.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318511     DOI: 10.1161/01.atv.13.7.1110

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  22 in total

Review 1.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

Review 3.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

4.  Impaired endothelium-dependent vascular reactivity in patients with familial combined hyperlipidaemia.

Authors:  M De Michele; A Iannuzzi; A Salvato; P Pauciullo; M Gentile; G Iannuzzo; S Panico; A Pujia; G M Bond; P Rubba
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

5.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

6.  Fish oil -- how does it reduce plasma triglycerides?

Authors:  Gregory C Shearer; Olga V Savinova; William S Harris
Journal:  Biochim Biophys Acta       Date:  2011-10-25

Review 7.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

8.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

9.  Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype.

Authors:  H Allayee; B E Aouizerat; R M Cantor; G M Dallinga-Thie; R M Krauss; C D Lanning; J I Rotter; A J Lusis; T W de Bruin
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

10.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

Authors:  S H Juo; S J Bredie; L A Kiemeney; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.